Sonoma Pharmaceuticals Announces Newly Published Results from Study of Hypochlorous Acid in Management of Hypertrophic and Keloid Scars

    NEXT STORY
    Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials
    PREV STORY
    Shire Files Submission for U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Roche purchases shares in tender offer for Spark Therapeutics, Inc.

    author_avatar
    NASDAQ Market News

    Cullinan Management Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

    author_avatar
    NASDAQ Market News

    AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™ (bremelanotide)

    WALTHAM, Mass., Feb. 03, 2017 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) announced today ...

    author_avatar
    NASDAQ Market News